Page 39 - Clinical News Today

New data presented includes: - First product candidate found to be effective in non-polyp patients in addition to polyp patients in a clinical trial, based on 100% of patients in both groups achieving SNOT-22 MCID at week 24 with LYR-210 (7500µg group) - - LYR-210 (7500µg) decreased ethmoid opacification at week 24, a measure of disease modification - - LYR-210 (7500µg) reduced the need for rescue medication - - Separately, Lyra also reported an analysis showing that LYR-210 (7500µg) achiev...

Photo Credit: IANS IANSLive London, April 12 (IANS) Patients treated with antipsychotic drugs have a lower risk of becoming infected or suffer a milder form of SARS-CoV-2 -- the virus causing Covid-19 -- if they get infected, according to a study. To get full access of the story, click here to subscribe to IANS News Service © 2021 IANS India Private Limited. All Rights Reserved. The reproduction of the story/photograph in any form will be liable for legal action. For news, views and gossips, ...

Applied DNA Sciences, Inc. and Takis Biotech/Evvivax: Applied DNA and Evvivax Announce Positive Preliminary Results of Phase I Clinical Trial for LinearDNA COVID-19 Vaccine Candidate in Felines - Strong Neutralizing Antibody Titer Elicited Across Cohort - Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, and its program development partner, Evvivax, S.R.L. ("Evvivax"), today announced positive preli...

MAGI’s Clinical Research vConference — Spring 2021 April 26-29 and May 3-6, 2021 • Join Us Virtually Want to solve the biggest clinical trial challenges? The answers are at MAGI’s Clinical Research vConference — Spring 2021. With 70+ sessions over eight days delivering a multitude of practical information using real-life examples, 180+ highly rated speakers with diverse expertise and backgrounds, and lots of time for audience interaction, attendees will find — and be able to implem...

(2) PRESS RELEASE Immunocore presents phase 3 data comparing tebentafusp with investigators choice in the clinical trial plenary session at the American Association for Cancer Research 2021 Annual Meeting Tebentafusp is the first investigational therapy to improve Overall Survival (OS) in patients with metastatic uveal melanoma First positive Phase 3 clinical trial for any T cell receptor therapeutic and first for any bispecific in a solid tumor (Nasdaq: IMCR), a late-stage biotechnology com...

(0) Dante Labs, a world leader in genomic sequencing and data analysis, announced today that it received ISO 13485:2016 certification for its Immensa Genomic Interpretation Software as a medical device. The highly coveted industry certification involved a deep clinical validation study carried out by several teams at Dante Labs over an 18 month period. The accreditation was awarded by The British Standards Institution (BSI) Group. This press release features multimedia. View the full release he...

Novavax Initiates COVID - 19 Vaccine Clinical Trial Crossover (Di martedì 6 aprile 2021) ... today announced the initiation of Crossover arms in two ongoing Clinical Trials of NVX - CoV2373, ... NVX - CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID - ...

Moleculin Biotech Engages IQVIA To Manage Potential COVID-19 Clinical Trial SOUTH SAN FRANCISCO (dpa-AFX) - Moleculin Biotech Inc. (MBRX) said that it has engaged IQVIA Biotech, a contract research organization, to manage the companys effort to begin potential clinical trials of WP1122 for the treatment of COVID-19. WP1122 is a prodrug of 2-DG, a well-known antimetabolite with the ability to inhibit glycolysis and alter glycosylation, two processes critical to coronaviruses like SARS-CoV-2, the...

(0) NEW YORK, NY / ACCESSWIRE / April 6, 2021 / Tarus Therapeutics Inc., an innovative biotechnology company developing adenosine receptor antagonists for cancer immunotherapy, today announced that it has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to proceed with a clinical study of TT-10, an oral small molecule drug targeting the Adenosine A2A receptor (A2AR). Tarus plans to initiate a Phase 1a/1b study in the third quar...

National April 4, 2021 KARACHI: Phase-III clinical trials of a triple-dose Chinese vaccine against Covid-19 have commenced at the University of Health Sciences (UHS), Lahore, and four other hospitals in Lahore as well as Faisalabad, officials said on Saturday, adding these trials would also commence at health facilities in Islamabad, Karachi and Jamshoro. “Clinical trials of a three-dose Chinese vaccine, dubbed as ZF-2001 have commenced at the University of Health Sciences (UHS) and four oth...